Fall Clinical News: Verrica’s P-315 Shows Promise in Phase 2 BCC Study
New research highlights the safety, tolerability, and antitumor effects of Verrica Pharmaceuticals Inc.’s P-315 in basal cell carcinoma. VP-315 is a novel oncolytic peptide under development for the treatment of basal cell carcinoma (BCC). The positive preliminary topline results from Part 2 of a Phase 2 study will be presented at Fall Clinical Dermatology Conference […]